CDNA Stock - CareDx, Inc
Unlock GoAI Insights for CDNA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $333.79M | $280.32M | $321.79M | $296.40M | $192.19M |
| Gross Profit | $224.16M | $178.32M | $209.58M | $199.01M | $129.08M |
| Gross Margin | 67.2% | 63.6% | 65.1% | 67.1% | 67.2% |
| Operating Income | $40.77M | $-203,363,000 | $-77,231,000 | $-29,726,000 | $-22,528,000 |
| Net Income | $52.55M | $-190,284,000 | $-76,613,000 | $-30,662,000 | $-18,714,000 |
| Net Margin | 15.7% | -67.9% | -23.8% | -10.3% | -9.7% |
| EPS | $1.00 | $-3.54 | $-1.44 | $-0.59 | $-0.40 |
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 26th 2025 | William Blair | Initiation | Market Perform | - |
| January 15th 2025 | Wells Fargo | Upgrade | Equal Weight | $24← $28 |
| August 28th 2024 | Wells Fargo | Initiation | Underweight | $28 |
| August 19th 2024 | BTIG Research | Upgrade | Buy | $40 |
| May 13th 2024 | Raymond James | Downgrade | Market Perform | - |
| May 1st 2024 | Craig Hallum | Upgrade | Buy | $15 |
| November 9th 2023 | Stephens | Upgrade | Overweight | $10 |
| August 15th 2023 | Raymond James | Upgrade | Outperform | $12 |
| May 11th 2023 | BTIG Research | Downgrade | Neutral | - |
| March 7th 2023 | Stephens | Downgrade | Equal Weight | $9← $19 |
| March 3rd 2023 | Craig Hallum | Downgrade | Hold | $9← $26 |
| March 3rd 2023 | Raymond James | Downgrade | Market Perform | - |
| April 25th 2022 | Stephens | Initiation | Overweight | $50 |
Earnings History & Surprises
CDNAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $0.24 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.13 | $0.28 | +115.4% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.12 | $0.10 | -16.7% | ✗ MISS |
Q2 2025 | Apr 30, 2025 | $0.06 | $0.09 | +50.0% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $0.05 | $0.18 | +260.0% | ✓ BEAT |
Q4 2024 | Nov 4, 2024 | $0.01 | $0.14 | +1300.0% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $-0.13 | $0.25 | +292.3% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.19 | $-0.03 | +84.2% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.24 | $-0.17 | +29.2% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.38 | $-0.18 | +52.6% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.42 | $-0.18 | +57.1% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-0.07 | $-0.11 | -57.1% | ✗ MISS |
Q1 2023 | Feb 27, 2023 | $-0.06 | $-0.07 | -16.7% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.14 | $-0.06 | +57.1% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.08 | $-0.13 | -62.5% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.05 | $-0.13 | -160.0% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.01 | $-0.03 | -192.4% | ✗ MISS |
Q4 2021 | Oct 28, 2021 | $0.01 | $0.07 | +483.3% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $0.05 | $0.11 | +120.0% | ✓ BEAT |
Latest News
Wells Fargo Maintains Equal-Weight on CareDx, Raises Price Target to $18
➖ NeutralCareDx Publishes Data On Third Manuscript From Surveillance HeartCare Outcomes Registry Shows Participants With Positive HeartCare Results Found At Higher Risk For Rejection-Related Complications
📈 PositiveCareDx Launches HistoMap Kidney, A Tissue-Based Gene Expression Test Advancing Precision Diagnosis In Kidney Transplant Rejection
📈 PositiveBTIG Maintains Buy on CareDx, Raises Price Target to $25
📈 PositiveCareDx shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveCareDx shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveCareDx Raises FY2025 Sales Guidance from $367.000M-$373.000M to $372.000M-$376.000M vs $368.883M Est
📈 PositiveCareDx Q3 Adj. EPS $0.28 Beats $0.14 Estimate, Sales $100.055M Beat $95.251M Estimate
📈 PositiveCareDx Announces Publication Of The Second Study From Surveillance Heartcare Outcomes Registry In The Journal Of The American College Of Cardiology; Second Shore Study Validates AlloSure Heart, An Integral Component Of Heartcare, As A Reliable Biomarker For Antibody-Mediated Rejection In Heart Transplant Recipients
📈 PositiveCareDx To Feature New IVD Products And IVDR Certification For AlloSeq Tx And QTYPE At ASHI 2025 Annual Meeting
📈 PositiveBTIG Reiterates Buy on CareDx, Maintains $22 Price Target
📈 PositiveBTIG Reiterates Buy on CareDx, Maintains $22 Price Target
📈 PositiveCareDx Urges Noridian To Preserve Coverage For Combination And Personalized Molecular Testing, Opposes Surveillance Limits And Bundled Payments In Draft LCD DL40060
➖ NeutralCareDx Submits Comment Letter On Draft Local Coverage Determination Policy
➖ NeutralWilliam Blair Initiates Coverage On CareDx with Market Perform Rating
➖ NeutralCareDx Non-GAAP EPS of $0.09 beats by $0.02, revenue of $84.39M misses by $0.14M
➖ NeutralFrequently Asked Questions about CDNA
What is CDNA's current stock price?
What is the analyst price target for CDNA?
What sector is CareDx, Inc in?
What is CDNA's market cap?
Does CDNA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CDNA for comparison